Status:
TERMINATED
Translating Neuroprediction Into Precision Medicine Via Brain Priming
Lead Sponsor:
Yale University
Conditions:
Autism Spectrum Disorder
Eligibility:
All Genders
5-9 years
Phase:
PHASE2
Brief Summary
The present study examines the impact of oxytocin (OXT) and Pivotal Response Treatment (PRT) on the development of language, social, and play skills in young children with Autism Spectrum Disorder (AS...
Detailed Description
This project investigates the effectiveness of a new intervention approach for Autism Spectrum Disorder (ASD) to optimize the effects of an evidence-based behavioral intervention, Pivotal Response Tre...
Eligibility Criteria
Inclusion
- Fit the age requirement: age 5-9
- Have been diagnosed previously with an ASD and meet criteria for ASD when characterized by research team
- Be in good medical health
- Be cooperative with testing
- Speak English in the family
- Successfully complete an fMRI scan
- Full-scale intelligence quotient (IQ)\>70
Exclusion
- Any metal or electromagnetic implants, including:
- Cardiac pacemaker
- Defibrillator
- Artificial heart valve
- Aneurysm clip
- Cochlear implants
- Shrapnel
- Neurostimulators
- History of metal fragments in eyes or skin
- Significant hearing loss or other severe sensory impairment
- A fragile health status.
- Current use of prescription psychotropic medications that may affect cognitive processes under study.
- A history of significant head trauma or serious brain or psychiatric illness
Key Trial Info
Start Date :
December 7 2018
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
July 28 2021
Estimated Enrollment :
5 Patients enrolled
Trial Details
Trial ID
NCT03370510
Start Date
December 7 2018
End Date
July 28 2021
Last Update
August 9 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Yale School of Medicine
New Haven, Connecticut, United States, 06520